Cost of medicines from Canada set to soar for millions of Americans
The U.S. Customs and Border Protection rule targets the de minimis exemption, which previously allowed shipments valued under $800 to pass through customs more easily.
Millions of Americans who obtain affordable medications from Canada could soon face higher costs due to a new U.S. Customs and Border Protection rule set to take effect later this month. The rule, targeted at lowering drug prices, suspends a de minimis exemption that previously permitted low-value shipments to enter the U.S. duty-free.
As a result, medications mailed from outside the U.S. will require additional data and a bond guarantee, potentially leading to delays, refusals, or greater difficulties in receiving prescribed drugs. Approximately 2.3 million Americans buy their drugs abroad, with the rule's impact particularly felt by those purchasing medications from Canadian pharmacies.
Advocates argue that the rule will hinder patients seeking affordable medicine, citing examples of skyrocketing costs for medications like Eliquis and Theophylline. President Donald Trump, who has prioritized lowering drug prices, has struck drug deals with pharmaceutical firms and launched the TrumpRx discounted-drug website. However, critics contend that the benefits of these initiatives do not extend to all medications or individuals.
Lawmakers from both parties have called for the administration to address concerns over access to affordable healthcare for Americans relying on medications from abroad.
Written by urgent.news from Global News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
